Literature DB >> 11252624

Multilevel models for survival analysis with random effects.

K K Yau1.   

Abstract

A method for modeling survival data with multilevel clustering is described. The Cox partial likelihood is incorporated into the generalized linear mixed model (GLMM) methodology. Parameter estimation is achieved by maximizing a log likelihood analogous to the likelihood associated with the best linear unbiased prediction (BLUP) at the initial step of estimation and is extended to obtain residual maximum likelihood (REML) estimators of the variance component. Estimating equations for a three-level hierarchical survival model are developed in detail, and such a model is applied to analyze a set of chronic granulomatous disease (CGD) data on recurrent infections as an illustration with both hospital and patient effects being considered as random. Only the latter gives a significant contribution. A simulation study is carried out to evaluate the performance of the REML estimators. Further extension of the estimation procedure to models with an arbitrary number of levels is also discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11252624     DOI: 10.1111/j.0006-341x.2001.00096.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  12 in total

Review 1.  Design and analysis of group-randomized trials: a review of recent methodological developments.

Authors:  David M Murray; Sherri P Varnell; Jonathan L Blitstein
Journal:  Am J Public Health       Date:  2004-03       Impact factor: 9.308

2.  A hierarchical frailty model applied to two-generation melanoma data.

Authors:  Tron Anders Moger; Marion Haugen; Benjamin H K Yip; Håkon K Gjessing; Ornulf Borgan
Journal:  Lifetime Data Anal       Date:  2010-11-04       Impact factor: 1.588

3.  Multilevel mixed linear models for survival data.

Authors:  Il Do Ha; Youngjo Lee
Journal:  Lifetime Data Anal       Date:  2005-03       Impact factor: 1.588

4.  On proportional hazards assumption under the random effects models.

Authors:  Ronghui Xu; Anthony Gamst
Journal:  Lifetime Data Anal       Date:  2007-07-19       Impact factor: 1.588

5.  Frailty modelling for survival data from multi-centre clinical trials.

Authors:  Il Do Ha; Richard Sylvester; Catherine Legrand; Gilbert Mackenzie
Journal:  Stat Med       Date:  2011-05-12       Impact factor: 2.373

6.  Joint modeling of recurrent events and a terminal event adjusted for zero inflation and a matched design.

Authors:  Cong Xu; Vernon M Chinchilli; Ming Wang
Journal:  Stat Med       Date:  2018-04-22       Impact factor: 2.373

7.  Design and analysis of the Community Youth Development Study longitudinal cohort sample.

Authors:  Eric C Brown; John W Graham; J David Hawkins; Michael W Arthur; Megan M Baldwin; Sabrina Oesterle; John S Briney; Richard F Catalano; Robert D Abbott
Journal:  Eval Rev       Date:  2009-06-09

8.  Identifying infants at increased risk for late initiation of immunizations: maternal and provider characteristics.

Authors:  Kristen A Feemster; C Victor Spain; Michael Eberhart; Susmita Pati; Barbara Watson
Journal:  Public Health Rep       Date:  2009 Jan-Feb       Impact factor: 2.792

9.  Comparison of risks of cardiovascular events in the elderly using standard survival analysis and multiple-events and recurrent-events methods.

Authors:  Edward H Ip; Achmad Efendi; Geert Molenberghs; Alain G Bertoni
Journal:  BMC Med Res Methodol       Date:  2015-03-08       Impact factor: 4.615

10.  The Magnetic Couples Study: protocol for a mixed methods prospective cohort study of HIV-serodifferent heterosexual couples' perspectives and use of pre-exposure prophylaxis (PrEP).

Authors:  James M McMahon; Janie Simmons; Jessica E Haberer; Sharon Mannheimer; Natalie M Leblanc; Leilani Torres; Robert Quiles; Guillermo Aedo; Anabel Javier; Amy Braksmajer; Graham Harriman; Nicole Trabold; Enrique R Pouget; Ann Kurth; Martez D R Smith; Judith Brasch; Eric J Podsiadly; Peter L Anderson
Journal:  BMJ Open       Date:  2021-07-01       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.